New Collaboration Between Panome Bio and Audubon Bioscience Revolutionizes Cancer Research Methods

Strategic Partnership to Enhance Cancer Research

Panome Bio, a prominent multi-omics contract research organization (CRO) that is also CLIA-certified, has officially announced its strategic partnership with Audubon Bioscience. This collaboration aims to streamline the cancer research process by providing an integrated path from ethical tissue acquisition to advanced metabolic discovery. The announcement was made during the AACR Annual Meeting 2026 in San Diego, California.

The Need for Integration

Historically, cancer researchers have faced significant challenges in accessing high-quality, ethically sourced biospecimens. The importance of such specimens cannot be overstated, as they are often pivotal in understanding cancer mechanisms and developing targeted therapies. The partnership between Panome Bio and Audubon Bioscience addresses this gap by offering a coordinated pathway for the procurement of formalin-fixed paraffin-embedded (FFPE) tissues, which are invaluable for complex studies.

Audubon Bioscience's impressive logistics and rigorous quality control ensure that only ethically obtained samples are used, making it an ideal partner for Panome Bio. With their established presence across 120 clinical sites globally, Audubon specializes in providing high-quality biospecimens, whether they are stones from fresh tissue, peripheral blood, or biofluids. This partnership brings forth a comprehensive approach to unlocking the potential of these precious resources.

Introducing TissueBridge™

A standout feature of this partnership is Panome Bio's innovative TissueBridge™ FFPE Metabolomics platform. It is the first of its kind designed specifically to handle FFPE samples and serves as a key to accessing the wealth of information lying dormant in these clinical archives. According to Tom Cohen, PhD, the President of Panome Bio, "Clinical archives are one of the most powerful and underutilized assets in cancer research". He emphasized that this collaboration not only aims to unlock existing data archives but also enhances flexibility and efficiency during the research process.

Advantages for Researchers

The benefits of this collaboration for researchers are manifold. By utilizing the TissueBridge™ platform together with Audubon's superior biobanking capabilities, researchers can achieve a seamless experience. They will now have access to high-quality FFPE tissue samples, which come equipped with comprehensive metadata, allowing for profound metabolic profiling. This integration is expected to accelerate timelines for biomarker discovery and facilitate retrospective cohort studies.

Researchers can engage in broader metabolic profiling without the initial burden of sample procurement logistics—efforts traditionally fraught with complexities. The partnership is designed to enable swift and reliable access to research-ready tissue samples that have been meticulously processed and characterized, thereby unlocking previously inaccessible insights.

Shared Vision for Improvement

Both Panome Bio and Audubon Bioscience share a vision for advancing cancer research through innovation. Rostyslav Semikov, PhD, the CEO of Audubon, stated, "Our aim is to ensure the biospecimens we provide truly impact research outcomes." Collaborating with Panome Bio continues this mission by enhancing the scope of research insights possible through their networks. This partnership allows for the pairing of tissue procurement with in-depth metabolomics, enriching the data landscape available to cancer researchers.

Engagement Opportunities

The collaboration will be prominently displayed at the AACR Annual Meeting 2026, where attendees can visit Booth #2015 to learn more about the advantages of the TissueBridge™ platform and the full range of multi-omic services offered by Panome Bio. Researchers interested in delving deeper into these services or inquiring about the partnership can also reach out directly via their dedicated contact channels.

This strategic collaboration marks a promising step forward in cancer research. Researchers equipped with the right tools and samples can delve deeper into understanding cancer biology, potentially leading to significant breakthroughs in diagnostics and therapies.

Conclusion

The partnership between Panome Bio and Audubon Bioscience is a vital development in the landscape of cancer research. By combining forces, they are set to eliminate existing bottlenecks and enhance the overall research experience, driving forward a new era for finding cures for cancer. With their combined expertise, they open up pathways that were previously limited, providing a vital resource that can potentially change the trajectory of cancer discovery efforts worldwide.